Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.48 |
| ▸ | MMP3 | P08254 | 5/20 | 0.48 |
| ▸ | APP | P05067 | 14/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP7 | P09237 | 2/20 | 0.41 |
| ▸ | MMP10 | P09238 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245763 | 0.91 | APP (0.47) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL7250754 | 0.88 | MMP1 (0.47) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL12494825 | 0.72 | LIPG (0.40) | — | |
| SCHEMBL7246490 | 0.66 | APP (0.51) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL13934039 | 0.66 | APP (0.73) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL14375097 | 0.66 | APP (0.73) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL4492455 | 0.65 | MMP1 (0.65) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL4498315 | 0.65 | MMP1 (0.65) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL4483832 | 0.64 | APP (0.75) | MMP1MMP3APPMMP2MMP7 | |
| SCHEMBL13934035 | 0.64 | APP (0.75) | MMP1MMP3APPMMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6525044-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| EP-1261610-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| WO-2001060826-A2 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055501-A1 | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production | APP, APH1A, APH1B | MMP1 4233/4885MMP3 4564/4885APP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.